| 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2025-074 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | | 浙江寿仙谷医药股份有限公司 关于部分募集资金投资项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2025 年 11 月 28 日，公司第五届董事会审计委员会 2025 年第三次会议、 第五届董事会第六次会议审议通过了《关于部分募集资金投资项目延期的议案》， 同意公司将"寿仙谷健康产业园保健食品建设项目（基本建设）"及"寿仙谷健 康产业园保健食品二期建设项目（基本建设）"的预定可使用状态日期从 2025 年 11 月 30 日调整为 2026 年 6 月 30 日。 本次对部分募集资金投资项目延期的事项，未调整项目的投资总额、建 设规模，不存在改变或变相改变募集资金用途和损害股东利益的情形。以上事项 在董事会审批权限范围内，无需提交股东大会审议。 一、募集资金基本情况 （一）2020 年公 ...

| 债券代码：113660 | 债券简称：寿 | 转债 22 | | | --- | --- | --- | --- | | 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2025-071 | 浙江寿仙谷医药股份有限公司 2026 年度日常关联交易预案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 是否需要提交股东会审议：是 公司 2026 年度日常关联交易预案系基于市场环境的变化以及公司生产 经营的实际需求制订，遵循了公平、公正、自愿、诚信的原则，符合公司及全体 股东的利益，不会导致公司对关联方形成较大的依赖，不会影响公司独立性。 一、日常关联交易基本情况 （一）审议程序 浙江寿仙谷医药股份有限公司（以下简称"寿仙谷"或"公司"）第五届董 事会审计委员会 2025 年第三次会议、第五届董事会第六次会议，审议通过了《浙 江寿仙谷医药股份有限公司 2026 年度日常关联交易预案》，关联董事李明焱先 生、李振皓先生和李振宇先生对该项议案回避表决。上述议案尚需提交公司股东 会审议，关联股东将在 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东会类型和届次 证券代码：603896 证券简称：寿仙谷 公告编号：2025-076 债券代码：113660 债券简称：寿 22 转债 浙江寿仙谷医药股份有限公司 关于召开2025年第二次临时股东会的通知 至2025 年 12 月 23 日 2025年第二次临时股东会 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东会召开当日的 9:15-15:00。 为更好地服务广大中小投资者，确保有投票意愿的中小投资者能够及时参会、 及时投票。公司拟使用上证所信息网络有限公司（以下简称"上证信息"）提供 的股东会提醒服务，委托上证信息通过智能短信等形式，根据股权登记日的股东 名册主动提醒股东参会投票，向每一位投资者主动推送股东会参会邀请、议案情 况等信息。投资者在收到智能短信后，可根据使用手 ...

| 债券代码：113660 | 债券简称：寿 22 | 转债 | | | --- | --- | --- | --- | | 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2025-070 | 浙江寿仙谷医药股份有限公司 第五届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江寿仙谷医药股份有限公司（以下简称"公司"）第五届董事会第六次会 议于 2025 年 11 月 28 日在公司会议室以现场结合通讯会议方式召开，会议通知 于 2025 年 11 月 24 日以电子邮件形式发出，会议应到董事 9 名，实到董事 9 名， 公司高级管理人员、董事会秘书、证券事务代表列席了会议。本次会议由董事长 李明焱先生主持，会议的召开符合《公司法》及《公司章程》的有关规定。 二、董事会会议审议情况 （一）审议并通过《浙江寿仙谷医药股份有限公司 2026 年度日常关联交易 预案》 为有效地保障公司正常生产经营活动的开展，公司对 2026 年度拟与关联方 进行的关联交易进行了预计。该日常关联交易对公司 ...

浙江寿仙谷医药股份有限公司 第五届董事会独立董事专门会议 2025年第二次会议决议 独立董事认为: 《浙江寿仙谷医药股份有限公司 2026 年度日常关联交易预 案》系基于公司生产经营的实际需求制订，遵循了公平、公正、自愿、诚信的原 则,符合《上海证券交易所上市公司自律监管指引第 5 号 --- 交易与关联交易》 等相关法律、法规和规范性文件及公司《关联交易管理制度》的规定;关联交易 的结算定价公允，不存在利益输送的情形，关联交易预计追加金额在公司整体经 营中占比较小，不会导致公司对关联方形成较大的依赖，不存在损害公司或股东 利益,特别是非关联股东和中小股东利益的情形;一致同意将该议案提交公司董 事会审议。在公司董事会对该议案进行表决时,关联董事应当按规定回避表决。 表决结果:同意票3票,反对票 0 票,弃权票 0 票。 门会议 浙江寿仙谷医药股份有 (本页无正文,为《浙江寿仙谷医药股份有限公司第五届董事会独立董事专门会 议 2025 年第二次会议决议》之签章页) 24 P 金 瑛 2025 年 11 月 28 日 浙江寿仙谷医药股份有限公司（以下简称"公司"）第五届董事会独立董事 专门会议 2025 年第二次 ...

Core Viewpoint - The company has announced a delay in the expected completion dates for two health food construction projects, adjusting them from November 30, 2025, to June 30, 2026, due to economic factors impacting investment risk management [1] Project Details - The first project, "Shouxiangu Health Industry Park Health Food Construction Project (Basic Construction)," has a planned investment of 224.27 million yuan [1] - The second project, "Shouxiangu Health Industry Park Health Food Phase II Construction Project (Basic Construction)," is set to invest 240.31 million yuan [1] - Funding for both projects is sourced from proceeds of publicly issued convertible bonds in 2020 and 2022, designated for basic construction of the industrial park [1] Economic Context - The delay is attributed to a sluggish global economic recovery and a slowdown in domestic economic growth, which has resulted in consumer spending not meeting expectations [1] - The company aims to control investment risks and prudently utilize raised funds, leading to the postponement of project timelines [1] Impact on Operations - The postponement does not alter the total investment amount, construction scale, or intended use of the projects [1] - The delay is stated to not harm shareholder interests and is not expected to have a significant adverse effect on the company's normal operations or overall fundraising arrangements [1]

Core Points - Zhejiang Shouxiangu Pharmaceutical Co., Ltd. successfully transferred the registration certificate for "Shouxiangu Brand Dendrobium and American Ginseng Tea" to its wholly-owned subsidiary Jinhua Shouxiangu Pharmaceutical Co., Ltd. [1] - The transfer of the registration certificate is part of a commitment made by the actual controller of the company and the sole investor of Wuyi County Fungi Research Institute, Li Mingyan, during the company's initial public offering [1] - The successful transfer of the registration certificate will not affect the normal production and sales of the "Shouxiangu Brand Dendrobium and American Ginseng Tea" product [1] Summary by Sections - **Company Actions** - The company has completed the transfer of the registration certificate for a health food product [1] - The transfer is part of fulfilling commitments related to the company's initial public offering [1] - **Regulatory Compliance** - Li Mingyan committed to applying for the cancellation of the Wuyi County Fungi Research Institute after the completion of the transfer of relevant health food registration certificates [1] - The commitment is irrevocable and remains valid from the date of issuance [1] - **Product Impact** - The transfer of the registration certificate will not impact the production and sales of the "Shouxiangu Brand Dendrobium and American Ginseng Tea" [1]

Core Viewpoint - The article discusses the recent movements of executives from Wahaha Group, highlighting their transitions to other companies and the implications for both the individuals and the organizations involved [6][7][19]. Group 1: Executive Movements - Shen Jiangang is now in charge of the fast-moving consumer goods (FMCG) business at Shouxiangu, while Guo Hong has been appointed as an independent non-executive director at October Rice Field, indicating a trend of Wahaha executives being sought after by other firms [6][7][9]. - Guo Hong's previous roles included significant responsibilities within Wahaha, and her experience in large-scale corporate operations is seen as valuable for October Rice Field's strategic upgrade [14][19]. - The departure of core executive Zhu Lidan from Wahaha has raised speculation about her future, as she was a key figure in the company [7][19]. Group 2: Company Performance and Strategy - October Rice Field is transitioning from a rice-selling company to a family food innovation enterprise, with a focus on enhancing management and operational capabilities [14][16]. - The company reported revenues of 45.33 billion, 48.67 billion, and 57.45 billion from 2022 to 2024, with net profits fluctuating from -5.64 billion to 2.04 billion during the same period [14]. - Shouxiangu is facing performance challenges, with a decline in revenue and net profit in 2023 and 2024, prompting a shift towards FMCG products to rejuvenate growth [16][19]. Group 3: Industry Trends - The article notes a trend of former Wahaha executives starting their own ventures or being recruited by other companies, indicating their high demand in the beverage industry [17][19]. - The competitive landscape in the beverage sector is evolving, with former Wahaha executives leveraging their experience to establish successful brands in various niches [17][19]. - The article highlights the importance of strategic management and operational efficiency in navigating the challenges faced by companies like October Rice Field and Shouxiangu [14][16].

Core Viewpoint - The successful transfer of the registration certificate for "Shouxiangu Brand Dendrobium and American Ginseng Tea" enhances the company's compliance with commitments related to its initial public offering and does not affect the normal production and sales of the product [1] Group 1 - The company’s wholly-owned subsidiary, Jinhua Shouxiangu Pharmaceutical Co., Ltd., has successfully acquired the registration certificate for the health food product [1] - The transfer of the registration certificate has been completed, while the transfer process for related health food product registration approvals is still ongoing [1] - The successful transfer supports the fulfillment of commitments associated with the company's initial public offering [1]

关于完成国产保健食品技术转让的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2025-069 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 | 22 转债 | | 浙江寿仙谷医药股份有限公司 近日，浙江寿仙谷医药股份有限公司（以下简称"公司"）全资子公司金华 寿仙谷药业有限公司（以下简称"寿仙谷药业"）成功受让由公司和武义县真菌 研究所（以下简称"真菌研究所"）共同持有的"寿仙谷牌铁皮石斛西洋参茶" 国产保健食品注册证书。具体情况如下： | 产品名称 | 寿仙谷牌铁皮石斛西洋参茶 | | | | --- | --- | --- | --- | | 保健功能 | 本品经动物实验评价，具有有助于增强免疫力的保健功能 | | | | 注册号 | 国食健注 G20250306 | | | | 有效期至 | 年 日 2030 09 | 月 20 | | | 注册人 | 金华寿仙谷药业有限公司 | | | | ...